MiNK Presents Clinical Data On Allogeneic iNKT Cells In Severe Respiratory Distress At The American Thoracic Society International Conference
Portfolio Pulse from Benzinga Newsdesk
MiNK Therapeutics presented clinical data on its allo-iNKTs (agenT-797) at the American Thoracic Society International Conference, showing a 75% survival rate in patients with severe respiratory distress. The treatment improved lung function, reduced inflammation, and secondary infections.
May 22, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MiNK Therapeutics' agenT-797 demonstrated positive clinical results in treating severe respiratory distress, potentially boosting the company's stock price.
The positive clinical data on agenT-797 presented at the American Thoracic Society International Conference indicates the potential for the treatment to be effective in treating severe respiratory distress. This could lead to increased interest in the company's stock and a potential rise in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100